Switch theme
Sign up to access all valuation multiples
PZ CORMAY SA is a manufacturer of diagnostic reagents and laboratory equipment. The company's products are used in Biochemistry, Hematology, Coagulation, Parasitology, Immunology, Urinalysis and Rapid tests.
2006
236
Last FY Revenue $21.8M
Last FY EBITDA $0.5M
$12.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, PZ CORMAY achieved revenue of $21.8M and an EBITDA of $0.5M.
PZ CORMAY expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PZ CORMAY valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $21.8M | XXX | XXX | XXX |
| Gross Profit | XXX | $8.9M | XXX | XXX | XXX |
| Gross Margin | XXX | 41% | XXX | XXX | XXX |
| EBITDA | XXX | $0.5M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 2% | XXX | XXX | XXX |
| EBIT | XXX | -$1.2M | XXX | XXX | XXX |
| EBIT Margin | XXX | -5% | XXX | XXX | XXX |
| Net Profit | XXX | -$1.2M | XXX | XXX | XXX |
| Net Margin | XXX | -5% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, PZ CORMAY's stock price is PLN 1 (or $0).
PZ CORMAY has current market cap of PLN 44.3M (or $11.7M), and EV of PLN 48.3M (or $12.8M).
See PZ CORMAY trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.8M | $11.7M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, PZ CORMAY has market cap of $11.7M and EV of $12.8M.
PZ CORMAY's trades at 0.6x EV/Revenue multiple, and 23.8x EV/EBITDA.
Equity research analysts estimate PZ CORMAY's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PZ CORMAY's P/E ratio is not available.
See valuation multiples for PZ CORMAY and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11.7M | XXX | $11.7M | XXX | XXX | XXX |
| EV (current) | $12.8M | XXX | $12.8M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 23.8x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -10.8x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -9.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPZ CORMAY's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $43K for the same period.
PZ CORMAY's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PZ CORMAY's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for PZ CORMAY and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 2% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $43K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 30% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Catapult | XXX | XXX | XXX | XXX | XXX | XXX |
| Optiscan Imaging | XXX | XXX | XXX | XXX | XXX | XXX |
| NanoFocus | XXX | XXX | XXX | XXX | XXX | XXX |
| Q-Interline | XXX | XXX | XXX | XXX | XXX | XXX |
| Jenoptik | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PZ CORMAY acquired XXX companies to date.
Last acquisition by PZ CORMAY was XXXXXXXX, XXXXX XXXXX XXXXXX . PZ CORMAY acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was PZ CORMAY founded? | PZ CORMAY was founded in 2006. |
| Where is PZ CORMAY headquartered? | PZ CORMAY is headquartered in Poland. |
| How many employees does PZ CORMAY have? | As of today, PZ CORMAY has 236 employees. |
| Is PZ CORMAY publicy listed? | Yes, PZ CORMAY is a public company listed on WAR. |
| What is the stock symbol of PZ CORMAY? | PZ CORMAY trades under CRM ticker. |
| When did PZ CORMAY go public? | PZ CORMAY went public in 2008. |
| Who are competitors of PZ CORMAY? | Similar companies to PZ CORMAY include e.g. Catapult, Optiscan Imaging, NanoFocus, Q-Interline. |
| What is the current market cap of PZ CORMAY? | PZ CORMAY's current market cap is $11.7M |
| Is PZ CORMAY profitable? | Yes, PZ CORMAY is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
